NIGERIAN TRIBUNE (press release) (blog) [ April 25, 2017 ] World Earth Day: Stakeholders canvass for adoption of biotechnology for food security Agriculture NIGERIAN TRIBUNE (press release) (blog) The Head of Agriculture Division of the ECOWAS Commission, Ernest Aubee, who spoke with Nigerian Tribune, said the ECOWAS has a biotechnology technology action plan which it is currently implementing across the 15 member states. The Nigerian ... Read the original: [ April 25, 2017 ] World Earth Day: Stakeholders canvass for adoption of biotechnology for food security Agriculture - NIGERIAN TRIBUNE (press... … Continue reading →

DUBLIN, Apr. 24, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Biotechnology Reagents Market 2017-2021" report to their offering. Research and Markets Logo The global biotechnology reagents market to grow at a CAGR of 10.13% during the period 2017-2021. The report, Global Biotechnology Reagents Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Ready-to-use reagents help minimize calculation, dilution, and pipetting errors. They reduce the duration of the diagnostic procedure and prevent contamination of samples. These factors have resulted in the demand for ready-to-use reagents among clinical laboratories and hospitals. According to the report, the biotechnology industry is spending a huge amount on R&D to innovate new techniques and technologies. The companies are more focused to improve the products, their quality, and standards. The biotech companies are majorly spending on protein synthesis, drug assessment, therapeutics, DNA and RNA analysis, and cell culture applications. Biotechnology reagents are used in all the processes. Further, the report states that biotechnology instruments are often … Continue reading →

LONDON, UNITED KINGDOM--(Marketwired - Apr 24, 2017) - Planda Biotechnology, Inc. (OTCQB: PLPL) ("Planda" or "the Company"), producer of the highly bioavailable Phytofare Catechin Complex, today announced that NutriBullet SuperFood Fat Burning Boost featuring Planda's Phytofare Catechin Complex will be available at retail outlets across the United States as early as May 2017.As announced last November, Capital Brands, the makers of NutriBullet SuperFoods, will now be featuring Planda's Phytofare Catechin Complex as the active ingredient in their product, SuperFood Fat Burning Boost.Capital Brands is expected to launch the revised product containing Phytofare with their retailers and on their website (nutriliving.com) as early as next month. Callum Cottrell-Duffield, Chief Operating Officer for Planda Biotechnology, commented, "We are excited to have Phytofare associated with such a fantastic brand as Nutribullet. Their use of Phytofare as an active ingredient in their reformulation is a clear indication of their commitment to use only the best ingredients to ensure that their customers receive a supremely effective product. It is also testimony to our shareholders that we are indeed on the right track and that our Phytofare ingredients are game changers for the supplement industry." NutriBullet has formulated specialized, plant-based SuperFood products using a variety of … Continue reading →

BBNS Vetr Inc. Downgrades iShares NASDAQ Biotechnology Index (IBB ... The Cerbat Gem iShares NASDAQ Biotechnology Index (NASDAQ:IBB) was downgraded by Vetr from a buy rating to a hold rating in a research note issued to investors on ... iShares NASDAQ Biotechnology Index (IBB) Earning Favorable ...BBNS all 4 news articles » Read the original: Vetr Inc. Downgrades iShares NASDAQ Biotechnology Index (IBB ... - The Cerbat Gem … Continue reading →

Two years after the $9 billion start-up unicorn Theranos crumbled, Silicon Valley still appears to be struggling to learn its lesson when it comes to health and medical start-ups. Improbable-sounding companies continue to turn up with tens of millions of dollars in funding, no published research to back them up, and nothing but criticism from scientists. Venture-capital firms insist that the standard that needs to be met for investment is much higher for medical start-ups, which must prove that their technology works with data, not just a pitch. And yet somehow, when these start-ups finally surface to public consciousness, they dont appear to pass even the most basic smell test with literally any experienced researcher in the field. There is a pervasive sense in Silicon Valley, bolstered by ten years of world-conquering success, that any sufficiently intelligent, sufficiently driven person can will what they want. But the move fast and break things mantra that has helped Silicon Valley disrupt countless industries over the last two decades is more dangerous when applied to medical scienceThe things being broken by health start-ups are laws of science and ironclad guidelines for research. When a health start-up moves fast and breaks things, it can … Continue reading →